focus -WSS

focus

author：hotspot 2025-09-06 08:25:01 - browse：59266

John Crowley pictured with his daughter Megan Crowley — health policy news from STAT — John Crowley pictured with his daughter Megan. Crowley family

WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John Crowley as its new CEO, the organization announced Tuesday.

Crowley came to biotech when his children were diagnosed with a rare genetic neuromuscular disease. He started working at Bristol Myers Squibb, and started Novazyme, which was eventually successful in creating an enzyme replacement therapy for Pompe disease. He later started and worked for several different biotech companies, most recently with Amicus Therapeutics, which had a drug approved to treat the disease in September.

The trade association’s board chair, Ted Love, served on the board of the company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

WSS

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

House looks to weaken Medicare negotiation

FDA does about

IVG is promising — but it won’t replace IVF quite yet

How to address the problem of discarded donor organs

Flu, Covid vaccination rates decline, new survey data show

knowledge

focus

hotspot

23andMe had bad news about my health. I wish a person had delivered it

In search for therapies for solid tumors, companies turn to claudin

How to save PrEP access — and even expand it

Clinical trials giant ICON acquires HumanFirst

Guidelines to prevent youth baseball injuries need more muscle

Nobel honors Karikó and Weissman's enduring partnership

Guidelines to prevent youth baseball injuries need more muscle

Some top drug companies are starting to take action on climate

Novavax promises a turnaround & Lilly roils the obesity market

In search for therapies for solid tumors, companies turn to claudin

hotspot

Study points to new risk in gene therapy death of Terry Horgan

A Q&A with Aletha Maybank, AMA’s chief health equity officer

The stability of $0 premiums in Medicare Advantage

AstraZeneca loses challenge to Medicare drug price negotiation

Scientists unlock the key to scar

International team creates first chimeric human

knowledge

focus

Wikipedia

knowledge